<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:mp ids='MP_0002055'>Diabetes</z:mp> has been shown to be a risk factor for age-related (AR) <z:hpo ids='HP_0000518'>cataract</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>As <z:chebi fb="0" ids="35664">statins</z:chebi> (<z:chebi fb="0" ids="35664">HMG-CoA reductase inhibitors</z:chebi>) are now commonly prescribed for patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, their impact on AR <z:hpo ids='HP_0000518'>cataract</z:hpo> prevalence should be considered </plain></SENT>
<SENT sid="2" pm="."><plain>This study determines associations between AR <z:hpo ids='HP_0000518'>cataract</z:hpo>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and reported <z:chebi fb="0" ids="35664">statin</z:chebi> use in a large optometric clinic population </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: In <z:hpo ids='HP_0000001'>all</z:hpo>, 6397 patient files (ages &lt;1-93 years) were reviewed </plain></SENT>
<SENT sid="4" pm="."><plain>Overall prevalence of <z:chebi fb="0" ids="35664">statin</z:chebi> use was calculated for patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 452) and without <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 5884) </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariable logistic regression analysis for AR <z:hpo ids='HP_0000518'>cataract</z:hpo> was performed controlling for patient sex, smoking, <z:mp ids='MP_0002842'>high blood pressure</z:mp>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and <z:chebi fb="0" ids="35664">statin</z:chebi> use </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The prevalence of <z:chebi fb="0" ids="35664">statin</z:chebi> use (in patients aged &gt;38 years) was 56% for those with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and 16% for those without <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was significantly associated with nuclear <z:mp ids='MP_0000612'>sclerosis</z:mp> (OR = 1.62, 1.14-2.29) and <z:hpo ids='HP_0100019'>cortical cataract</z:hpo> (OR = 1.37, 1.02-1.83) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> use was associated with nuclear <z:mp ids='MP_0000612'>sclerosis</z:mp> (OR = 1.48, 1.09-2.00) and <z:hpo ids='HP_0007787'>posterior subcapsular cataract</z:hpo> (OR = 1.48, 1.07-2.04) </plain></SENT>
<SENT sid="9" pm="."><plain>The 50% probability of <z:hpo ids='HP_0000518'>cataract</z:hpo> in <z:chebi fb="0" ids="35664">statin</z:chebi> users occurred at age 51.7 and 54.9 years in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and without <z:mp ids='MP_0002055'>diabetes</z:mp>, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>In non-<z:chebi fb="0" ids="35664">statin</z:chebi> users, it was significantly later at age 55.1 and 57.3 years for patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and without <z:mp ids='MP_0002055'>diabetes</z:mp>, respectively (p &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In this population, <z:chebi fb="0" ids="35664">statin</z:chebi> use was substantially higher in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and was associated with AR <z:hpo ids='HP_0000518'>cataracts</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Further long-term study is warranted to recommend monitoring of crystalline lenses in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> benefiting from <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
</text></document>